PURPOSE: No therapy has ever shown prolongation of survival in stage IV metastatic melanoma. The association of cytokine-induced autoimmunity with improved prognosis led us to investigate the effect of multi-epitope melanoma vaccines alone and in combination with cytokines in this Eastern Cooperative Oncology Group multicenter phase II trial. EXPERIMENTAL DESIGN:Eligible patients were required to have failed prior therapies and to be HLA-A2 positive. Three HLA class I-restricted lineage antigen epitopes were administered in a factorial 2x2 design. Peptide vaccine alone (arm A), or combined with granulocyte-monocyte colony-stimulating factor (GM-CSF; Immunex) 250 microg/d subcutaneously for 14 of 28 days each month (arm B), or combined with IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week (arm C), or combined with both IFN-alpha2b and GM-CSF (arm D). The primary endpoint was immune response measured by enzyme-linked immunospot assay; secondary endpoints were clinical antitumor response, disease-free survival, and overall survival. RESULTS:One hundred twenty patients enrolled and 115 patients were analyzed. Immune responses to at least one melanoma antigen were observed in 26 of 75 (35%) patients with serial samples. Neither IFN-alpha2b nor GM-CSF significantly improved immune responses. Six objective clinical responses were documented. At a median follow-up of 25.4 months, the median overall survival of patients with vaccine immune response was significantly longer than that of patients with no immune response (21.3 versus 13.4 months; P=0.046). CONCLUSION: Immune response to vaccination correlates with prolonged survival in patients with metastatic melanoma and is not enhanced by immunomodulatory cytokines as tested in this trial.
RCT Entities:
PURPOSE: No therapy has ever shown prolongation of survival in stage IV metastatic melanoma. The association of cytokine-induced autoimmunity with improved prognosis led us to investigate the effect of multi-epitope melanoma vaccines alone and in combination with cytokines in this Eastern Cooperative Oncology Group multicenter phase II trial. EXPERIMENTAL DESIGN: Eligible patients were required to have failed prior therapies and to be HLA-A2 positive. Three HLA class I-restricted lineage antigen epitopes were administered in a factorial 2x2 design. Peptide vaccine alone (arm A), or combined with granulocyte-monocyte colony-stimulating factor (GM-CSF; Immunex) 250 microg/d subcutaneously for 14 of 28 days each month (arm B), or combined with IFN-alpha2b (Intron A; Schering-Plough) 10 million units/m2 three times a week (arm C), or combined with both IFN-alpha2b and GM-CSF (arm D). The primary endpoint was immune response measured by enzyme-linked immunospot assay; secondary endpoints were clinical antitumor response, disease-free survival, and overall survival. RESULTS: One hundred twenty patients enrolled and 115 patients were analyzed. Immune responses to at least one melanoma antigen were observed in 26 of 75 (35%) patients with serial samples. Neither IFN-alpha2b nor GM-CSF significantly improved immune responses. Six objective clinical responses were documented. At a median follow-up of 25.4 months, the median overall survival of patients with vaccine immune response was significantly longer than that of patients with no immune response (21.3 versus 13.4 months; P=0.046). CONCLUSION: Immune response to vaccination correlates with prolonged survival in patients with metastatic melanoma and is not enhanced by immunomodulatory cytokines as tested in this trial.
Authors: Svetomir N Markovic; Vera J Suman; James N Ingle; Judith S Kaur; Henry C Pitot; Charles L Loprinzi; Ravi D Rao; Edward T Creagan; Mark R Pittelkow; Jakob B Allred; Wendy K Nevala; Esteban Celis Journal: Am J Clin Oncol Date: 2006-08 Impact factor: 2.339
Authors: Stergios J Moschos; Howard D Edington; Stephanie R Land; Uma N Rao; Drazen Jukic; Janice Shipe-Spotloe; John M Kirkwood Journal: J Clin Oncol Date: 2006-07-01 Impact factor: 44.544
Authors: Kimberly A Chianese-Bullock; Jennifer Pressley; Courtney Garbee; Sarah Hibbitts; Cheryl Murphy; Galina Yamshchikov; Gina R Petroni; Eric A Bissonette; Patrice Y Neese; William W Grosh; Priscilla Merrill; Robyn Fink; Elizabeth M H Woodson; Catherine J Wiernasz; James W Patterson; Craig L Slingluff Journal: J Immunol Date: 2005-03-01 Impact factor: 5.422
Authors: Michal Lotem; Yangbing Zhao; John Riley; Patrick Hwu; Richard A Morgan; Steven A Rosenberg; Maria R Parkhurst Journal: J Immunother Date: 2006 Nov-Dec Impact factor: 4.456
Authors: Ulrich Keilholz; Cornelis J A Punt; Martin Gore; Wim Kruit; Poulam Patel; Danielle Lienard; Jose Thomas; Thomas M Proebstle; Alexander Schmittel; Dirk Schadendorf; Thierry Velu; Sylvie Negrier; Ulrich Kleeberg; Frederic Lehman; Stefan Suciu; Alexander M M Eggermont Journal: J Clin Oncol Date: 2005-09-20 Impact factor: 44.544
Authors: Roland Kaufmann; Konstanze Spieth; Ulrike Leiter; Cornelia Mauch; Peter von den Driesch; Thomas Vogt; Ruthild Linse; Wolfgang Tilgen; Dirk Schadendorf; Jürgen C Becker; Günther Sebastian; Sven Krengel; Lutz Kretschmer; Claus Garbe; Reinhard Dummer Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Rosalie M Luiten; Esther W M Kueter; Wolter Mooi; Maarten P W Gallee; Elaine M Rankin; Winald R Gerritsen; Shirley M Clift; Willem J Nooijen; Pauline Weder; Willeke F van de Kasteele; Johan Sein; Paul C M van den Berk; Omgo E Nieweg; Anton M Berns; Hergen Spits; Gijsbert C de Gast Journal: J Clin Oncol Date: 2005-10-31 Impact factor: 44.544
Authors: Craig L Slingluff; Gina R Petroni; Galina V Yamshchikov; Sarah Hibbitts; William W Grosh; Kimberly A Chianese-Bullock; Eric A Bissonette; Donna L Barnd; Donna H Deacon; James W Patterson; Jayashree Parekh; Patrice Y Neese; Elizabeth M H Woodson; Catherine J Wiernasz; Priscilla Merrill Journal: J Clin Oncol Date: 2004-11-15 Impact factor: 44.544
Authors: Ronald J C L M Vuylsteke; Barbara G Molenkamp; Hester A Gietema; Paul A M van Leeuwen; Pepijn G J T B Wijnands; Wim Vos; Paul J van Diest; Rik J Scheper; Sybren Meijer; Tanja D de Gruijl Journal: Cancer Res Date: 2004-11-15 Impact factor: 12.701
Authors: Sarah E Church; Shawn M Jensen; Christopher G Twitty; Keith Bahjat; Hong-Ming Hu; Walter J Urba; Bernard A Fox Journal: Cancer J Date: 2011 Sep-Oct Impact factor: 3.360
Authors: Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea Journal: Clin Cancer Res Date: 2018-01-04 Impact factor: 12.531
Authors: Craig L Slingluff; Sandra Lee; Fengmin Zhao; Kimberly A Chianese-Bullock; Walter C Olson; Lisa H Butterfield; Theresa L Whiteside; Philip D Leming; John M Kirkwood Journal: Clin Cancer Res Date: 2013-05-07 Impact factor: 12.531
Authors: Craig L Slingluff; Gina R Petroni; Walter C Olson; Mark E Smolkin; Merrick I Ross; Naomi B Haas; William W Grosh; Marc E Boisvert; John M Kirkwood; Kimberly A Chianese-Bullock Journal: Clin Cancer Res Date: 2009-11-10 Impact factor: 12.531
Authors: Renee Vermeij; Toos Daemen; Geertruida H de Bock; Pauline de Graeff; Ninke Leffers; Annechien Lambeck; Klaske A ten Hoor; Harry Hollema; Ate G J van der Zee; Hans W Nijman Journal: Clin Dev Immunol Date: 2010-09-15